A Trial of ABSK043, an Oral PD-L1 Inhibitor, in Patients With Angiogenic Sarcomas
NCT07014137
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
20
Enrollment
OTHER
Sponsor class
Conditions
Sarcoma
Interventions
DRUG:
ABSK043 single agent
Sponsor
University Health Network, Toronto